Atherosclerotic Cardiovascular Disease (ASCVD)

Amarin Corporation presented new *in vitro* data at ESC Congress 2025 regarding VASCEPA®/VAZKEPA® (EPA). The research demonstrated EPA’s potential to reduce inflammation in atherosclerotic cardiovascular disease (ASCVD) by modulating the ATP-P2X7 axis and NLRP3 inflammasome in macrophages. Additionally, EPA inhibited lipoprotein(a) [Lp(a)] oxidation, mitigating oxidative stress and pro-inflammatory protein expression in endothelial cells. These findings suggest cardiovascular benefits of EPA may extend beyond triglyceride reduction, potentially offering further risk mitigation.